Teva Pharmaceutical Industries Limited Stock TEL AVIV STOCK EXCHANGE
Equities
TEVA
IL0006290147
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,140 ILa | +0.99% | -0.73% | +60.94% |
Sales 2024 * | 15.95B 5,912B | Sales 2025 * | 16.54B 6,131B | Capitalization | 19.17B 7,109B |
---|---|---|---|---|---|
Net income 2024 * | 820M 304B | Net income 2025 * | 1.39B 514B | EV / Sales 2024 * | 2.14 x |
Net Debt 2024 * | 14.93B 5,533B | Net Debt 2025 * | 12.41B 4,600B | EV / Sales 2025 * | 1.91 x |
P/E ratio 2024 * |
17.9
x | P/E ratio 2025 * |
12.3
x | Employees | 35,737 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.44% |
Latest transcript on Teva Pharmaceutical Industries Limited
1 day | +0.99% | ||
1 week | -0.73% | ||
1 month | +16.46% | ||
3 months | +30.67% | ||
6 months | +69.38% | ||
Current year | +60.94% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 59 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-30 | 6,140 | +0.99% | 1,607,669 |
24-05-29 | 6,080 | +0.12% | 768,673 |
24-05-28 | 6,073 | -0.21% | 1,258,396 |
24-05-27 | 6,086 | -0.26% | 174,639 |
24-05-26 | 6,102 | -1.34% | 335,935 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 30, 2024 at 10:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- TEVA Stock
- TEVA Stock